- Home
- NAUT vs TVGN Comparison
NAUT vs TVGN Comparison
Compare NAUT & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAUT | TVGN |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Blank Checks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.4M | 89.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NAUT | TVGN |
|---|---|---|
| Price | $1.86 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 345.8K | ★ 1.4M |
| Earning Date | 10-28-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $0.38 |
| 52 Week High | $2.54 | $1.92 |
Technical Indicators
Market Signals| Indicator | NAUT | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 40.35 |
| Support Level | $1.96 | $0.39 |
| Resistance Level | $2.13 | $0.47 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 5.86 | 16.21 |
Price Performance
Historical ComparisonAbout NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.